Beijing Anshi Biotechnology Co

Avistone Biotechnology is a pioneering biopharmaceutical company focused on developing innovative treatments for advanced non-small cell lung cancer (NSCLC) with cMET alterations. Operating in the highly specialized oncology market, Avistone serves patients and healthcare providers by advancing precision medicine through targeted therapies. The company’s business model revolves around the research, development, and commercialization of novel drugs, with revenue generated from clinical trials, licensing agreements, and eventual drug sales. Avistone's flagship products include cMET inhibitors like bozitinib and vebreltinib, which are currently undergoing rigorous clinical trials to ensure efficacy and safety. By leveraging cutting-edge science and strategic partnerships, Avistone aims to address unmet medical needs and improve patient outcomes in the oncology space.

Keywords: biopharmaceutical, NSCLC, cMET inhibitors, precision medicine, oncology, clinical trials, bozitinib, vebreltinib, targeted therapies, drug development.